Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo.
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX.
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its lead clinical program.
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration .
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company will present a company presentation and participate in one-on-one.